MedTrace Logo

Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum

NCT01113424 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2012-07-10

No results posted yet for this study

Summary

Bioequivalence between oral nicotine replacement products and Nicorette® gum.

Conditions

  • Tobacco Dependence

Interventions

DRUG

Nicotine

Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg

DRUG

Nicorette® (Nicotine Gum)

Single-dose of marketed nicotine gum 2 mg or 4 mg

Sponsors & Collaborators

  • McNeil AB

    lead INDUSTRY

Principal Investigators

  • Elisabeth Kruse, PhD · McNeil AB

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2008-11-30
Completion
2008-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01113424 on ClinicalTrials.gov